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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Acute kidney injury (AKI) significantly increases the risk of mortality in
patients following cardiovascular intervention procedures. This study was carried out to inves-
tigate the incidence, predictors, and prognostic implications of AKI after thoracic endovascular
aortic repair (TEVAR) of Stanford type B aortic dissection.
Methods: A total of 156 patients with Stanford type B aortic dissection who underwent TEVAR
were retrospectively analyzed between February 1, 2004 and October 31, 2011. Multivariable
regression was used to predict risk factors for AKI. Association between baseline characteris-
tics, postoperative AKI, and mortality during follow up was evaluated.
Results: AKI was identified in 48 (30.8%) of 156 patients, with seven (14.5%) patients requiring
continuous renal replacement therapy. The in-hospital mortality rate was 0% in patients
without AKI and 12.5% in those with AKI (p Z 0.001). Univariate analysis identified preopera-
tive chronic kidney disease, acute dissection, complicated dissection, malperfusion complica-
tions with comprehensive complications, and postoperative minimum estimated glomerular
filtration rate within 48 hours as associated with AKI. Malperfusion complications [odds ratio
(OR)Z 4.828; 95% confidence interval (CI)Z 1.163e20.03] were the only independent predic-
tor of AKI. Patients suffering from AKI had a 14-fold increased risk for 30-day mortality
(ORZ 14.3; 95% CIZ 1.7e118.4; pZ 0.014) and a 10-fold increased risk for 1-year mortality
(OR Z 9.5; 95% CI Z 2.02e44.9; p Z 0.004).have no conflicts of interest relevant to this article.
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The incidence, risk factors, and prognosis of AKI 613Conclusion: A significant rate of AKI was observed following TEVAR and was associated with an
increase in 30-day and 1-year mortality. Malperfusion complications were identified as an in-
dependent predictor of AKI.
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Acute kidney injury (AKI) is a common complication after
cardiovascular intervention procedures.1,2 Furthermore,
the development of postoperative AKI following elective
abdominal aortic aneurysm (AAA) and endovascular aortic
repair (EVAR) has been associated with prolonged hospital
stays and a significantly increased risk of mortality.3,4
However, ranges of reported renal dysfunction of patients
undergoing thoracic EVAR (TEVAR) were highly variable
according to different criteria, varying from 11.9% to
34.0%.5,6 TEVAR involves the insertion and deployment of a
stent graft through the femoral artery. The less invasive
nature of endovascular treatment provides better in-
hospital survival and a less invasive alternative to open
surgery for type B aortic dissection.7 TEVAR has been
increasingly used to treat type B aortic dissection. How-
ever, type B dissection differs from AAA and other aortic
diseases in many aspects. There is little information
focusing on AKI after TEVAR for type B aortic dissection.
The clinical risks and implications of acute renal dysfunc-
tion following TEVAR for type B aortic dissection have not
been well studied.
The objective of this study was to investigate the inci-
dence, predictors, and prognostic implications of AKI
following TEVAR in patients with Stanford type B aortic
dissection.Materials and methods
Patient population and procedural details
We retrospectively analyzed a total of 186 patients who
underwent thoracic endovascular repair from February 1,
2004 to October 31, 2011 in Nanjing First Hospital affiliated
with Nanjing Medical University. Of these, 156 patients with
Stanford type B aortic dissection were included in the
present analysis. We excluded 30 patients due to the
following conditions: (1) stent-graft placement was tech-
nically unsuccessful, (2) patients died 24 hours after the
procedure, (3) no data on renal function were available, (4)
patients were already on dialysis before the procedure, or
(5) patients had aneurysms of the descending thoracic
aorta, penetrating aortic ulcers, or traumatic aortic
transection.
Details of the arterial anatomy evaluation and implan-
tation procedure for these patients have been described
previously.8 The type of anesthesia (local anesthesia with
conscious sedation or general anesthesia) was determined
by clinical status and patient preference. After graft-stent
deployment, contrast aortography was performed to assess
outcome.After the procedure, patients were transferred to the
coronary care unit (CCU). Serum creatinine (Cr) and blood
urea nitrogen values were measured 24 hours before the
procedure, immediately after the procedure, and then
once daily during hospitalization. Indications for continuous
renal replacement therapy (CRRT) were refractory pulmo-
nary edema or fluid overload, metabolic acidosis, hyper-
kalemia, uremic symptoms, persistent oliguria (urine
output < 200 mL/12 hours) or anuria (urine output <
50 mL/12 hours).
All patients underwent coronary angiography. When at
least one main vessel of the epicardial coronary arteries
had >70% stenosis, percutaneous coronary intervention
(PCI) was carried out within 2 weeks after the TEVAR
procedure.
Our institutional review board approved the study, and
informed consent was obtained from each patient.
Definitions
Aortic dissection was considered an acute event if it
occurred within the first 14 days from the onset of symp-
toms, and as chronic if it occurred after 14 days. The term
“complicated dissection” was defined as persistent or un-
relenting back pain despite maximal medical therapy, un-
controllable hypertension, aortic enlargement more than
5 mm/year, malperfusion syndromes, or (imminent)
rupture.9
The baseline glomerular filtration rate (GFR) was
calculated with the abbreviated Modification of Diet in
Renal Disease formula [estimated GFR (eGFR; mL/minute/
1.73 m2) Z 186  serum Cre1.154  agee0.203  0.742, if
female  (1.210 if African American)].10 Chronic renal
failure was defined as a baseline eGFR  60 mL/minute/
1.73 m2.11
Patients with AKI were identified by a 25% decrease in
eGFR, a 1.5-fold increase in serum Cr compared with
baseline at 48 hours following the procedure (RIFLE classi-
fication),12 or the need for CRRT during index
hospitalization.
Malperfusion complications were caused by branch
arterial obstruction secondary to the aortic dissection,
including ischemia and/or infarction of the celiac trunk or
renal, mesenteric, and limb vasculature. They were judged
on the basis of clinical or imaging data.
Follow up
Clinical follow up was conducted at 1, 6, and 12 months
after discharge, and annually thereafter by telephone or
through a clinical visit. Patients were followed for a period
from 6 to 101 months (mean: 33.8  22.5 months). A total
of 15 patients (9.6%) were immediately lost to follow up
after discharge.
Table 1 Baseline clinical characteristics of patient population (n Z 156).
Parameter All Non-AKI AKI p Number of
observations
Total cases 156 108 (69.2%) 48 (30.8%) 156
Clinical background
Age (y; 30e85) 54.8  11.0 54.8  11.5 (n Z 108) 53.7  9.9 (n Z 48) 0.544 156
Male 138 (88.5%) 95 (88.0%) 43 (89.6%) 0.770 156
Hypertension 102 (67.1%) 73 (69.5%) 29 (61.7%) 0.343 152
Hypertension level 0.056 145
0 50 (34.5%) 32 (32.3%) 18 (39.1%)
1 6 (4.1%) 5 (5.1%) 1 (2.2%)
2 30 (20.7%) 26 (26.3%) 4 (8.7%)
3 59 (40.7%) 36 (36.4%) 23 (50.0%)
Diabetes 11 (7.1%) 8 (7.4%) 3 (6.3%) 1.000 156
Hyperlipidemia 6 (3.8%) 3 (2.8%) 3 (6.3%) 0.555 156
Current smoking 87 (55.8%) 61 (56.5%) 26 (54.2%) 0.788 156
CAD 39 (35.1%) 27 (36.0%) 12 (33.3%) 0.783 111
Previous PCI 3 (1.9%) 2 (1.9%) 1 (2.1%) 1.000 156
Previous MI 0 0 0 d 156
Previous CABG 0 0 0 d 156
Previous stroke 11 (7.1%) 8 (7.4%) 3 (6.3%) 1.000 156
COPD 8 (5.1%) 5 (4.6%) 3 (6.3%) 0.976 156
Clinical
presentation
Preoperative
creatinine (mmol/L),
median
(interquartile range)
82.7
(70.6e110.3)
82.4
(71.0e101.2; n Z 108)
80.4
(69.1e130.9; n Z 48)
0.292 156
Preoperative CKD
(eGFR  60 mL/
minute/1.73 m2)
35 (22.4%) 19 (17.6%) 16 (33.3%) 0.030 156
Preoperative eGFR
(mL/min/1.73 m2)
0.046 156
>90 72 (46.2%) 50 (46.3%) 22 (45.8%)
60e89 49 (31.4%) 39 (36.1%) 10 (20.8%)
30e59 31 (19.9%) 18 (16.7%) 13 (27.1%)
<29 4 (2.6%) 1 (0.9%) 3 (6.3%)
Acute dissection 126 (80.8%) 82 (75.9%) 44 (91.7%) 0.021 156
Complicated dissection 43 (27.6%) 24 (22.2%) 19 (39.6%) 0.025 156
Heart rate (beats/min) 77.5  13.2 76.5  12.9 (n Z 106) 79.7  13.7 (n Z 48) 0.169 154
Hemoglobin (g/dL) 130.8  17.3 131.8  16.9 (n Z 107) 128.7  18.2 (n Z 47) 0.323 154
Ejection fraction (%),
median
(interquartile range)
64 (60e67) 64 (60.0e67.0) (n Z 92) 65 (61.0e68.0) (n Z 42) 0.335 134
AOD (mm) 37.2  4.7 37.0  4.8 (n Z 92) 37.6  5.6 (n Z 42) 0.565 134
LVDd (mm), median
(interquartile range)
52.0 (49.0e56.0) 51.0 (49.0e56.3) (n Z 92) 52.0 (49.5e56.0)
(n Z 42)
0.937 134
Medical treatment
b-Blocker 123 (80.4%) 87 (80.6%) 36 (80.0%) 0.937 152
ACEI/ARB 105 (69.1%) 75 (70.1%) 30 (66.7%) 0.676 152
Calcium antagonist 117 (76.5%) 81 (75.0%) 36 (80%) 0.506 152
Values are median with interquartile range, mean  standard deviation, or number (%). For hypertension levels, see Mancia G et al.31
ACEIZ angiotensin-converting enzyme inhibitor; AKIZ acute kidney injury; AODZ ascending aorta root diameter; ARBZ angiotensin
receptor blocker; CABGZ coronary artery bypass graft; CADZ coronary artery disease; CKDZ chronic kidney disease; COPDZ chronic
obstructive pulmonary disease; eGFR Z estimated glomerular filtration rate; LVDd Z left ventricular end diastolic dimension;
MI Z myocardial infarction; PCI Z percutaneous coronary intervention; TEVAR Z thoracic endovascular aortic repair.
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Continuous variables are presented as mean  standard
deviation if normally distributed and as median (inter-
quartile range) if not normally distributed. Categorical
variables are given as frequencies and percentages.
Continuous variables were tested for differences with the
Student t test or ManneWhitney U test. Categorical vari-
ables were tested for differences with the Chi square test
or Fisher exact t test. A forward stepwise multivariable
logistic regression model was applied to identify predictors
of AKI after TEVAR. A Cox proportional hazard model was
applied to identify predictors of death after TEVAR. In
addition, the KaplaneMeier method was used to estimate a
cumulative survival plot relating AKI to incidence. Survival
was compared with the log-rank test. Results are reported
as adjusted odds ratio (OR) with 95% confidence interval
(CI). A two-sided p < 0.05 was considered statistically sig-
nificant. All analyses were conducted with SPSS Statistics
version 16.0.0 (SPSS Inc., Chicago, IL, USA).Results
Baseline characteristics of study population
patients
We retrospectively analyzed a total of 186 patients who
underwent thoracic endovascular repair from February 1,
2004 to October 31, 2011. A total of 30 patients were
excluded according to the exclusion criteria. A total of 156
patients (average age: 54.8  11.0 years) with Stanford
type B aortic dissection were included in the present
analysis. Of the 156 patients, 138 (88.5%) were male and 18
(11.5%) were female patients.
Common comorbidities were hypertension (67.1%), dia-
betes (7.1%), smoking history (55.8%), coronary artery dis-
ease (35.1%), previous stroke (7.1%), history of previous
percutaneous artery intervention (1.9%), and chronic
obstructive pulmonary disease (COPD; 5.1%). These comor-
bidities are summarized in Table 1. TEVAR was performed in
126 (80.8%) patients during the acute phase and in 30 (19.2%)
patients during the chronic phase in the interventional
catheterization lab. The underlying disease and baseline
characteristics of patients undergoing TEVAR are shown in
Table 1. PCI was performed in eight patients with coronary
heart disease during the perioperative period.
Incidence of postprocedural AKI
AKI according to the RIFLE classification12 occurred in 48
patients (30.8%) after TEVAR, seven patients (4.5%) needed
CRRT, of which four (2.6%) patients died in the hospital;
another three patients survived (one patient was trans-
ferred to continue hemodialysis, one patient maintained
chronic renal insufficiency, and one patient had complete
recovery of renal function).
The AKI incidence was related to preoperative chronic
kidney disease (CKD; 33.3% vs. 17.6%,pZ 0.030), acute aortic
dissection (91.7% vs. 75.9%, p Z 0.021), complicated aortic
dissection (22.2% vs. 39.6%, p Z 0.025), malperfusioncomplications (18.8% vs. 7.4%, pZ 0.036), and preoperative
eGFR (pZ 0.046), but was independent of age, hypertension,
current smoking status, COPD, left ventricular ejection frac-
tion, left ventricular end-diastolic diameter, heart rate, pre-
operative serum Cr, and preoperative hemoglobin (Table 1).
Compared with the non-AKI group, AKI patients showed
significantly increased postoperative serum Cr levels (p <
0.001) and decreased eGFR (47.4  22.9 vs.
80.7  21.8 mL/minute/1.73 m2; p < 0.001) within 48 hours
after TEVAR and comprehensive complications (29.2%
vs.12.0%; p Z 0.009). The length of stay in the CCU was
longer in patients with AKI [4 (2e6) days vs. 3 (2e4) days;
p Z 0.021]. However, endograft leak (type I); LSCA (left
subclavian artery) total coverage, stroke, red blood cell
transfusion, peak leukocyte count, peak lactic acid, peak
glutamic oxaloacetic transaminase, and peak glutamic py-
ruvic transaminase levels after TEVAR were not significantly
different between the AKI and non-AKI groups (Table 2).
Malperfusion complications were celiac trunk ischemia
(n Z 1), acute renal ischemia, and/or infarction (n Z 5),
mesenteric ischemia and/or infarction (n Z 2), and limb
ischemia (n Z 9). Interestingly, no significant difference
was seen in the contrast medium doses between the two
groups (p Z 0.081). Changes in eGFR of postoperative
TEVAR are shown in Fig. 1.
Predictors for AKI after TEVAR
Multivariable logistic regression analysis identified malper-
fusion complications (OR Z 4.828; 95% CI Z 1.163e20.03)
as an independent predictor for AKI.
Mortality
In-hospital mortality rate was 3.8% (6 of 156 patients). Of
all the patients within the first 30 days after TEVAR, 4.5% (7
of 156) died. The 1-year mortality rate was 5.8% (9 of 156
patients).
A total of six patients died in the hospital. The causes of
death for these patients were multiorgan failure (n Z 1),
muscle dissolution following lower limb ischemia (n Z 1),
distal aneurysm rupture (nZ 1), cerebral infarction (nZ 1),
and ischemic bowel disease (nZ 2). Another seven patients
died during the follow-up period. The causes of death in these
patients were intracerebral bleeding (nZ 1), retrograde tear
Stanford type A aortic dissection (nZ 1), myocardial infarc-
tion (nZ 1), and unknown cause (nZ 4).
Mortality at 30 days (12.5%  4.8% vs. 0.9%  0.9%;
p Z 0.001), 6 months (14.9%  5.2% vs. 2.0%  1.4%;
p Z 0.001), and 1 year (17.4%  5.6% vs. 2.0%  1.4%;
p Z 0.001) was significantly higher in patients with post-
procedural AKI than in those without AKI. Survival at 1 year
was significantly lower in patients with postprocedural AKI
(82.6%  5.6% vs. 98.0%  1.4%; p < 0.001), but did not
differ between the two groups at 6 years after TEVAR
(77.4%  0.8% vs. 78.2%  12.8%; p > 0.05; Fig. 2).
All patients who died in the hospital belonged to the AKI
group. Patients suffering from AKI had a 14-fold increased
risk for 30-day mortality (OR Z 14.3; 95% CI Z 1.7e118.4;
pZ 0.014) and a 10-fold increased risk for 1-year mortality
(OR Z 9.5; 95% CI Z 2.02e44.9; p Z 0.004; Table 3).
Table 2 Perioperative and postoperative characteristics of patient population (n Z 156).
Parameter All Non-AKI AKI p Number of
observations
Total cases 156 108 (69.2%) 48 (30.8%) 156
Perioperative data
Stent length (mm), median
(interquartile range)
150.0 (127.0e157.0) 150.0 (127.0e160.0;
n Z 108)
150.0 (125.0e157.0;
n Z 47)
0.705 155
Contrast medium volume (mL) 238.22  65.57 231.45  61.17
(n Z 93)
252.20  65.57
(n Z 45)
0.081 138
General anesthesia 146 (93.6%) 99 (91.7%) 47 (97.9%) 0.264 156
Endoleak (type I) 12 (9.0%) 5 (12.2%) 7 (7.5%) 0.383 134
LSCA total coverage 30 (22.4%) 18 (19.4%) 12 (29.3%) 0.205 134
Retrograde aortic dissection 0 0 0 d 134
PCI 8 (5.1%) 6 (5.6%) 2 (4.2%) 1.000 156
Laboratory data
Creatinine postoperative day 1
(mmol/L), median
(interquartile range)
90.0 (74.0e113.7) 84.8 (72.4e98.4;
n Z 105)
111.7 (83.8e141.9;
n Z 48)
<0.001 153
Creatinine postoperative day 2
(mmol/L), median
(interquartile range)
92.1 (74.6e116.4) 84.5 (73.0e104.2;
n Z 103)
126.6 (97.8e171.4;
n Z 46)
<0.001 149
Postoperative minimum
eGFR within 48 h
70.7  26.9 80.7  21.8
(n Z 108)
47.4  22.9
(n Z 48)
<0.001 156
Peak GOT (U/L),
median (interquartile range)
28.0 (17.0e50.0) 27.0 (17.0e50.0;
n Z 105)
30 (18.0e45.0;
n Z 47)
0.742 152
Peak GPT (U/L), median
(interquartile range)
28.0 (18.0e69.0) 30.0 (15.0e70.0;
n Z 105)
25.0 (19.0e67.0;
n Z 47)
0.720 152
Postoperative peak lactic acid
(mmol/L), median
(interquartile range)
1.7 (1.3e2.5) 1.7 (1.3e2.5;
n Z 99)
1.7 (1.4e2.7;
n Z 46)
0.870 145
Postoperative minimum
hemoglobin (g/dL)
103.8  16.3 105.3  14.6
(n Z 107)
100.5  19.5
(n Z 47)
0.129 154
Peak leukocyte count (109/L) 13.6  3.9 13.4  3.8
(n Z 108)
14.1  4.3
(n Z 47)
0.290 155
In-hospital complications
Postoperative stroke 9 (5.8%) 5 (4.6%) 4 (8.3%) 0.587 156
Malperfusion complications 17 (10.9%) 8 (7.4%) 9 (18.8%) 0.036 156
Postoperative MI 0 0 0 d 156
Postoperative paraplegia 0 0 0 d 156
Multiple organ failure 2 (1.3%) 0 (0%) 2 (4.2%) 0.093 156
Comprehensive complications (any
of the aforementioned
complications)
27 (17.3%) 13 (12.0%) 14 (29.2%) 0.009 156
Death in hospital 6 (3.8%) 0(0%) 6 (12.5%) 0.001 156
Reversible disturbance of
consciousness
18 (11.5%) 9 (8.3%) 9 (18.8%) 0.060 156
Blood transfusion 12 (7.7%) 6 (5.6%) 6 (12.5%) 0.239 156
CRRT 7 (4.5%) 0 (0%) 7 (14.6%) <0.001 156
Postoperative days in CCU, median
(interquartile range)
3.0 (2.0e5.0) 3.0 (2.0e4.0;
n Z 108)
4.0 (2.0e6.0;
n Z 48)
0.021 156
Postoperative days in hospital, median
(interquartile range)
13.0 (9.0e16.0) 14.0 (10.0e16.3;
n Z 108)
13.0 (9.0e17.0;
n Z 48)
0.816 156
AKI Z acute kidney injury; CCU Z coronary care unit; CRRT Z continuous renal replacement therapy; eGFR Z estimated glomerular
filtration rate; GOT Z glutamic oxaloacetic transaminase; GPT Z glutamic pyruvic transaminase; LSCA Z left subclavian artery;
MI Z myocardial infarction; PCI Z percutaneous coronary intervention.
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In contrast to previous research, the present study focused
on postoperative acute renal function change and prognosisof patients with aortic type B dissection following TEVAR.
The major findings based on our results were: (1) acute
renal injury following TEVAR in patients with aortic type B
dissection was associated with malperfusion complications;
Figure 1 Incidence of postprocedural AKI after TEVAR ac-
cording to changes in GFR. AKI was determined based on risk,
injury, and failure status according to the RIFLE classification.
AKI Z acute kidney injury; GFR Z glomerular filtration rate;
TEVAR Z thoracic endovascular aortic repair.
Figure 2 Cumulative survival according to the occurrence of
periprocedural acute kidney injury (AKI). Survival of patients
with and without AKI after endovascular intervention for type B
dissection (TEVAR). KaplaneMeier estimates of overall cumu-
lative survival rate in both groups; p Z 0.02 by log-rank test.
TEVAR Z thoracic endovascular aortic repair.
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type B dissection was associated with poor short-term and
middle-term survival.
Based on an inconsistent definition of AKI and differ-
ences in research populations, a wide range of incidence of
renal dysfunction has been reported in patients undergoing
TEVAR. In a series of 175 patients (including those with
thoracic aortic aneurysms, Stanford type B aortic dissec-
tions, penetrating thoracic ulcers, and traumatic aortic
transection) undergoing TEVAR, Pisimisis and co-workers7
reported 11.9% of patients with postoperative AKI (per
the RIFLE classification). Chang et al13 reported 32% of
patients with postoperative acute renal insufficiency (in-
crease > 50% in preprocedural serum Cr) in patients un-
dergoing complex endovascular thoracoabdominal
aneurysm repair. The RIFLE classification is a more sensitive
indicator of renal function and can be used as a risk factor
to predict long-term survival, which was suggested by the
Acute Dialysis Quality Initiative Group.2 In our study, we
focused on renal functional analysis of patients with type B
aortic dissection undergoing TEVAR according to the RIFLE
classification. The incidence of AKI was observed to be
30.8% in patients undergoing TEVAR, which was similar to
the value of 34% reported by Eggebrecht et al,5 confirming
that acute renal injury after TEVAR is a common problem in
patients with type B aortic dissection.
Because all patients needed to undergo coronary angi-
ography, and some patients underwent PCI, larger volumes
of contrast medium were used in our study compared with a
previous study,7 which may contribute to the higher inci-
dence of AKI. Contrast-induced nephropathy (CIN) is a
widely recognized cause for renal dysfunction in interven-
tional procedures, especially in patients with pre-existing
renal insufficiency.14 Interestingly, the amount of contrast
media used in the AKI group compared with that used in the
non-AKI group did not reach statistical significance in the
present study, inconsistent with a previous report.5 CIN isgenerally defined as an increase in serum Cr over 25% or
44 mmol from the baseline value 48e72 hours after contrast
medium administration in the absence of any other etiol-
ogy.15 However, aortic dissection often results in tearing of
blood vessels and renal ischemia. Contrast agents are not
likely to be the only factor that causes AKI after TEVAR. We
speculate that the mechanisms of CIN should not be the
major cause of the occurrence of postoperative AKI in pa-
tients with type B aortic dissection undergoing TEVAR.
Impaired renal function at baseline has been identified
as a risk factor for AKI after multivariate adjustment for
comorbidities in the settings of endovascular AAA repair
(EVAR), sepsis, PCI, and cardiac surgery.16 In our study,
preoperative eGFR level and CKD were associated with AKI.
Although previous studies showed that preoperative renal
dysfunction was a significant and independent risk factor
for death after endovascular aneurysm repair,17 our data
showed there was no statistically significant correlation
between preoperative CKD and mortality. A possible
explanation for this discrepancy is that the pathological
changes of aortic dissection are different from aortic
aneurysm. Preoperative CKD alone does not play an
important role in the mortality that follows TEVAR.
Our study showed acute aortic dissection and compli-
cated dissection were associated with an increased risk of
AKI following TEVAR. Data from Eggebrecht and col-
leagues18 indicated that marked inflammation occurs after
TEVAR, especially in patients with acute aortic pathology
(e.g., acute dissection or aortic transection). The devel-
opment of inflammation may, therefore, contribute to the
occurrence of AKI. Furthermore, emergency interventions
were often prompted by complications of the dissection
with an inherently increased individual risk as compared
with chronic dissection. Nevertheless, the acute phase
repair of acute complicated type B aortic dissection should
not be altered or discontinued on the basis of AKI, inasmuch
Table 3 Cox regression analysis of association between clinical characteristics and outcome.
30-day mortality 1-year mortality
OR (95% CI) p OR (95% CI) p
Hypertension 0.49 (0.09e2.42) 0.380 0.38 (0.10e1.43) 0.152
Preoperative creatinine 1.01 (0.99e1.02) 0.501 1.0 (0.99e1.02) 0.507
Preoperative CKD (eGFR  60 mL/min/1.73 m2) 0.57 (0.07e4.71) 0.600 0.87 (0.18e4.08) 0.855
Peak leukocyte count (109/L) 1.16 (0.98e1.39) 0.090 1.16 (0.96e1.29) 0.150
Postoperative peak lactic acid 1.52 (1.22e1.89) <0.001 1.39 (1.13e1.71) 0.002
Malperfusion complications 5.19 (1.01e26.8) 0.049 3.95 (1.02e15.29) 0.047
CRRT 39.5 (8.68e179.7) <0.001 21.21 (5.90e76.20) <0.001
Comprehensive complications 31.7 (3.82e263.89) 0.001 8.396 (2.364e29.82) 0.001
Acute dissection 28.1 (0.01e87,508) 0.416 28.20 (0.03e23,214) 0.330
AKI 14.3 (1.72e118.4) 0.014 9.52 (2.02e44.87) 0.004
AKI Z acute kidney injury; CI Z confidence interval; CKD Z chronic kidney disease; CRRT Z continuous renal replacement therapy;
eGFR Z estimated glomerular filtration rate; OR Z odds ratio.
618 J.-C. Zhu et al.as survival rates without TEVAR are poor.19 In our study,
although various factors were associated with AKI in the
univariate analysis, only malperfusion complications
remained predictive in the multivariate analysis. There
were some possible explanations for this strong association.
Aortic dissection is one of the most frequent causes of
vascular acute serious complications, such as visceral
ischemic necrosis (bowel, liver, kidney, and limb) with
possible organ failure, shock, usually due to obliteration of
splanchnic arteries by the intimal flap.20 Acute renal
ischemia induces severe alterations of the endothelium in
small peritubular arterioles and capillaries, postischemic
interstitial inflammation and microvasculopathy, both of
which contribute to ongoing renal dysfunction.21 Further-
more, acute artery endothelial injury, vital organ malper-
fusion, ischemia-reperfusion injury, rhabdomyolysis, and
hemodynamic instability were also important causes of
acute renal failure.22e25
Development of AKI is an important factor in the mor-
tality of patients after other interventional procedures.2,26
Despite some studies reporting that CRRT is associated with
a better prognosis in patients with AKI,27 the impact of
CRRT on outcomes of patients with severe AKI after TEVAR
has not been explored. Our study showed that AKI neces-
sitating CRRT following TEVAR was associated with
increased 30-day and 1-year mortality. In this study, 30-day
and 1-year survival rates were lower in patients with AKI
compared with those without AKI. However, there were no
differences in survival at 6 years after TEVAR. Although the
study populations were not identical, these findings are
similar to previous reports.5 Renal function is usually
improved over time rather than being deteriorated after
TEVAR in complicated dissection.28 These indicate that
postoperative AKI after TEVAR may only have impact on
short- and medium-term survival of patients, with no sig-
nificant effects on long-term survival, whereas TEVAR itself
plays a crucial role in long-term prognosis of patients.
Although previous studies showed that oral administration
of N-acetylcysteine, adequate hydration, use of gadolinium
contrast agents, and withdrawal of nephrotoxic drugs are
recommended in patients at risk for AKI,29,30 further
studies are warranted to evaluate AKI prevention following
TEVAR.There were several limitations associated with this
study. First, it was a retrospective, uncontrolled study.
Second, some patients were lost to follow up and some data
were unobtainable, making results less accurate. Third,
only univariate Cox regression analysis for mortality was
presented because the event count was not sufficient to
support multivariate analysis with inclusion of all mortality
predictors in our study. Thus, a multivariate model would
not have been appropriate.
Our data suggest that postprocedural AKI was a common
complication of thoracic aortic stent-graft repair in type B
aortic dissection. Malperfusion complications were the only
independent predictor of postprocedural AKI identified,
and the occurrence of postprocedural AKI was a strong
predictor of 30-day and 1-year mortality after TEVAR.
Because TEVAR has become a more widely practiced pro-
cedure, strategies to further reduce postprocedural AKI
should be investigated.
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